Orquest Healos
This article was originally published in The Gray Sheet
Executive Summary
Bone graft substitute is as safe and effective as an autograft in spinal fusion procedures, according to results of a randomized, 29-patient, two-center European study. The findings, presented at Eurospine 1999 on Sept. 11, show that 10 of 13 Healos patients and 13 of 16 autograft patients were considered successfully treated at 12 months. Use of a substitute for autograft in spinal fusions is expected to avoid difficulties related to the harvesting procedure - including an increase in surgery time, longer hospital stays and post-operative disability. U.S. clinical trials of Healos are under way
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.